The Effect of the ALDH2 Gene Polymorphism on the Propofol Potency for Inducing Loss of Consciousness

Propofol Clinical Trial

Official title:

The Effect of the ALDH2 Gene Polymorphism on the Propofol Potency for Inducing Loss of Consciousness in Cardiac Patients: a Prospective Observational Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03762538
• Other study ID #: EAGLES
• Status: Not yet recruiting
• Start date: February 1, 2019
• Est. completion date: December 31, 2019

Study information

• Verified date: January 2018
• Source: Shanghai Zhongshan Hospital
• Contact: Kefang Guo, MD
• Phone: +86-13817706936
• Email: drguokefang[@]foxmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to determine whether ALDH2 gene polymorphisms (G/G, G/A A/A) have effect on the potency of propofol.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: December 31, 2019
• Est. primary completion date: June 30, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

• ASA II

Exclusion Criteria:

• ASA III-IV

• OSAS

• hepatic and renal insufficiency

Related Conditions & MeSH terms

• Propofol
• Unconsciousness

Intervention

Drug:
• Propofol
Patients will be induced to unconsciousness using propofol intravenously.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect-site concentration	patient's effect-site concentration when he/she loss consciousness	immediately after patient lose his/her consciousness